MedTrace Logo

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

NCT01874483 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2016-01-27

No results posted yet for this study

Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 187004 following multiple dose administration over 14 days.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

placebo

DRUG

BI 187004

BI 187004, dose 2

DRUG

BI 187004

BI 187004, dose 4

DRUG

BI 187004

BI 187004, dose 5

DRUG

BI 187004

BI 187004, dose 6

DRUG

BI 187004

BI 187004, dose 7

DRUG

BI 187004

BI 187004, dose 1

DRUG

BI 187004

BI 187004, dose 3

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874483 on ClinicalTrials.gov